Treatment of Hyperthyroidism in Graves’ Disease Complicated by Thyroid Eye Disease

Abstract Thyroid eye disease (TED) is the most consequential extrathyroidal manifestation or complication of Graves’ disease (GD). Treatment of hyperthyroidism in GD complicated by TED is challenging. Antithyroid drugs (ATDs) and thyroidectomy do not change the natural course of TED, while radioactive iodine (RAI) is associated with a small but well-documented risk of TED de novo occurrence or its progression/worsening. In the presence of mild TED, any treatment for hyperthyroidism can be used, but should RAI treatment be selected, steroid prophylaxis (short course of low-dose prednisone) is strongly recommended if TED is of recent onset and/or risk factors for progression exist. In moderate-to-severe and active TED, ATDs are the preferred treatment but thyroidectomy is a valid option. RAI ablation is generally avoided, but it might be used when the clinical situation calls for it but with extreme caution if an aggressive treatment for TED with high-dose glucocorticoids (with or without orbital radiotherapy) is administered concomitantly. In moderate-to-severe and inactive TED, all three treatments for hyperthyroidism are acceptable, and steroid prophylaxis in RAI-treated patients should be given when risk factors for TED progression are identified. Management of sight-threatening TED represents the absolute priority, and hyperthyroidism should be controlled with ATDs until TED has been cured.